[1]马雅楠 金晓雪 刘德敏 卢蕊 谷国强.CTRP9对冠心病合并2型糖尿病患者冠状动脉钙化的预测价值[J].心血管病学进展,2022,(6):572.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.021]
　MA Yanan,JIN Xiaoxue,LIU Demin,et al.Predictive Value of CTRP9 on Coronary Artery Calcification in Patients with Coronary Heart Disease Complicated with Type 2 Diabetes Mellitu[J].Advances in Cardiovascular Diseases,2022,(6):572.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.021]
点击复制

CTRP9对冠心病合并2型糖尿病患者冠状动脉钙化的预测价值()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年6期
页码:
572
栏目:
论著
出版日期:
2022-06-25

文章信息/Info

Title:
Predictive Value of CTRP9 on Coronary Artery Calcification in Patients with Coronary Heart Disease Complicated with Type 2 Diabetes Mellitu
作者:
马雅楠 金晓雪 刘德敏 卢蕊 谷国强
(河北医科大学第二医院心内科,河北 石家庄 050000)
Author(s):
MA Yanan;  JIN Xiaoxue;  LIU Demin;  LU Rui;  GU Guoqiang
(Department of Cardiology,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China)
关键词:
C1q肿瘤坏死因子相关蛋白9; 2型糖尿病; 冠状动脉钙化
Keywords:
CTRP9;  Type 2 diabetes mellitus;  Coronary artery calcification
DOI:
10.16806/j.cnki.issn.1004-3934.2022.06.021
摘要:
目的 探讨C1q肿瘤坏死因子相关蛋白9（CTRP9）对2型糖尿病（T2DM）患者冠状动脉钙化（CAC）的预测价值。方法 收集2021年3月—12月在河北医科大学第二医院住院的201例冠心病患者资料。根据是否存在T2DM和CAC分为4组：无糖尿病无钙化患者（对照组）32例，单纯CAC患者（CAC组）45例，单纯T2DM患者（T2DM组）50例和T2DM合并CAC患者（T2DM+CAC组）74例。采用ELISA法检测各组患者血浆CTRP9水平。采用多因素logistic回归分析评估CTRP9是否为T2DM患者CAC的独立危险因素，并通过受试者工作特征曲线评估CTRP9对T2DM患者合并CAC的预测价值。结果 四组患者在年龄、吸烟史、高血压、心力衰竭、糖化血红蛋白、空腹血糖、高密度脂蛋白胆固醇、载脂蛋白A1、肌红蛋白、乳酸脱氢酶、β2微球蛋白、CTRP9方面比较，差异有统计学意义（P<0.05）。与T2DM组相比，T2DM+CAC组患者的年龄较大，男性、高血压患者占比增高，高密度脂蛋白胆固醇、CTRP9水平显著降低，差异均有统计学意义。多因素logistic回归分析显示，年龄和高血压均为糖尿病患者CAC的独立危险因素，CTRP9为CAC的保护因素。受试者工作特征曲线显示，血浆CTRP9水平预测T2DM患者CAC曲线下面积为0.747（敏感度为78.4%，特异度为78.0%）。结论 CTRP9是CAC的保护因素，血浆CTRP9水平对T2DM患者发生CAC具有良好的预测价值。
Abstract:
Objective To explore the predictive value of CTRP9 for coronary artery calcification (CAC) in patients with type 2 diabetes mellitus (T2DM). Methods The data of 201 patients with coronary heart disease admitted to the Second Hospital of Hebei Medical University from March 2021 to December 2021 were collected. The patients were divided into 4 groups based on the presence or absence of T2DM and CAC:control group (no coronary calcification and diabetes,32 cases),CAC group (CAC without T2DM,45 cases),T2DM group(T2DM without CAC,50 cases) and T2DM+CAC group (T2DM combined with CAC,74 cases). Plasma CTRP9 levels were measured using a commercial enzyme-linked immunosorbent assay kit. Using multivariable logistic regression analysis to assess whether CTRP9 independent risk factor for CAC in patients with T2DM and the predictive value of CTRP9 in patients with T2DM complicated with CAC was evaluated by ROC curve. Results There were significant differences in age,smoking history,hypertension,heart failure,HbA1c,GLU,HDL-C,APOA,MYO,LDH,β2MG and CTRP9 among the four groups (P<0.05). Compared with the T2DM group,the age of the T2DM+CAC group was older,the proportion of male and hypertensive patients was higher,and the levels of HDL-C and CTRP9 were significantly lower,the differences were statistically significant. Multivariate logistic regression analysis showed that age and hypertension were independent risk factors for CAC in diabetic patients ,and CTRP9 was a protective factor for CAC. The ROC curve showed that the plasma CTRP9 level predicted that the area under the CAC curve in diabetic patients was 0.747 (sensitivity 78.4% ,specificity 78.0%). Conclusion CTRP9 is a protective factor of CAC,and the decrease of plasma CTRP9 level has a good predictive value in patients with T2DM complicated with CAC

参考文献/References:


[1] Kedhi E,Joesoef KS,McFadden E,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice(COMPARE):a randomised trial[J]. Lancet,2010,375(9710):201-209.

[2] Shaw LJ,Giambrone AE,Blaha MJ,et al. Long-term prognosis after coronary artery calcification testing in asymptomatic patients:a cohort study[J]. Ann Intern Med,2015,163(1):14-21.

[3] Yahagi K,Kolodgie FD,Lutter C,et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus[J]. Arterioscler Thromb Vasc Biol,2017,37(2):191-204.

[4] Orringer CE,Blaha MJ,Blankstein R,et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction[J]. J Clin Lipidol,2021,15(1):33-60.

[5] Chen TC,Yen CK,Lu YC,et al. The antagonism of 6-shogaol in high-glucose-activated NLRP3 inflammasome and consequent calcification of human artery smooth muscle cells[J]. Cell Biosci,2020,10:5.

[6] Yang Y,Li Y,Ma Z,et al. A brief glimpse at CTRP3 and CTRP9 in lipid metabolism and cardiovascular protection[J]. Prog Lipid Res,2016,64:170-177.

[7] 姚希,张凯旋. 血清Apelin和补体C1q肿瘤坏死因子相关蛋白9与糖尿病肾病慢性肾脏病Ⅴ期患者血管钙化的关系[J]. 中华实用诊断与治疗杂志,2020,34(9):955-958.

[8] Miyatake N,Adachi H,Nomura-Nakayama K,et al. Circulating CTRP9 correlates with the prevention of aortic calcification in renal allograft recipients[J]. PLoS One,2020,15(1):e0226526.

[9] 王伟民,霍勇,葛均波. 冠状动脉钙化病变诊治中国专家共识（2021版）[J]. 中国介入心脏病学杂志,2021,29(5):251-259.

[10] Madhavan MV,Tarigopula M,Mintz GS,et al. Coronary artery calcification:pathogenesis and prognostic implications[J]. J Am Coll Cardiol,2014,63(17):1703-1714.

[11] Yang R,Zhu Y,Wang Y,et al. HIF-1α/PDK4/autophagy pathway protects against advanced glycation end-products induced vascular smooth muscle cell calcification[J]. Biochem Biophys Res Commun,2019,517(3):470-476.

[12] Malik S,Zhao Y,Budoff M,et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis[J]. JAMA Cardiol,2017,2(12):1332-1340.

[13] Yu XH,Zhang DW,Zheng XL,et al. C1q tumor necrosis factor-related protein 9 in atherosclerosis:Mechanistic insights and therapeutic potential[J]. Atherosclerosis,2018,276:109-116.

[14] Ahmed SF,Shabayek MI,Abdel Ghany ME,et al. Role of CTRP3, CTRP9 and MCP-1 for the evaluation of T2DM associated coronary artery disease in Egyptian postmenopausal females[J]. PLoS One, 2018,13(12):e0208038.

[15] Jung CH,Lee MJ,Kang YM,et al. Association of serum C1q/TNF-related protein-9 concentration with arterial stiffness in subjects with type 2 diabetes[J]. J Clin Endocrinol Metab,2014,99(12):E2477-E2484.

[16] He C,Wang J,Yin Y,Li Z. Automated classification of coronary plaque calcification in OCT pullbacks with 3D deep neural networks[J]. J Biomed Opt,2020,25(9):095003.

[17] Vrachimis A,Honold L,Faust A,et al. New molecular probes of vascular inflammation[J]. Q J Nucl Med Mol Imaging,2016,60(3):194-204.

[18] Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.

[19] Fujino A,Mintz GS,Lee T,et al. Predictors of calcium fracture derived from balloon angioplasty and its effect on stent expansion assessed by optical coherence tomography[J]. JACC Cardiovasc Interv,2018,11(10):1015-1017.

相似文献/References:

[1]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
　LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[2]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
　LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(6):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[3]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
　XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[4]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
　GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[5]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
　WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(6):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[6]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
　XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(6):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[7]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
　SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[8]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
　MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[9]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
　ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[10]吴易航 张宇辉 张健.SGLT2 i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展,2020,(8):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
　WU Yihang,ZHANG Yuhui,ZHANG Jian.Progresses on the Cardiovascular Protection of SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(6):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]

更新日期/Last Update: 2022-08-05